Counterfeit Pharmaceuticals: A Major Threat to Public Health

The document analyzes the proliferation of counterfeit pharmaceuticals, which the WHO estimates constitute more than 50% of the global drug market. It highlights a severe crisis in Africa, where up to 70% of medicines in some countries like Nigeria are estimated to be counterfeit, leading to significant mortality from diseases like malaria. The brief discusses the role of high R&D costs and patents in creating market exclusivity that drives the poor toward cheaper, fake alternatives. It evaluates 'Track & Trace' technologies and international initiatives like IMPACT, while noting that weak enforcement and a lack of quality data hinder policy formulation. Finally, it explores pharmaceutical foreign direct investment (FDI) in the SADC region as a potential path toward legitimate market growth.

• Counterfeit medicines represent a massive portion of the global pharmaceutical market, with the WHO estimating they make up more than 50% of the market, while the US FDA estimates the figure is over 10%.
• The burden of counterfeit drugs is disproportionately high in Africa, where seven out of ten pharmaceutical products are estimated to be counterfeit, compared to only one in ten in developed countries.
• Counterfeit pharmaceuticals cause significant mortality in Africa; in 2003, the WHO reported that 200,000 of the approximately 1 million annual malaria deaths were due to fake anti-malarial drugs.
• High costs of drug development and patent protections create market exclusivity and high prices, which drive vulnerable populations in developing countries toward cheaper counterfeit alternatives.
• Economic losses from counterfeit drugs are substantial in East Africa, with Kenya, Burundi, Tanzania, Uganda, and Rwanda reporting annual tax losses exceeding $500 million.
• Technological 'Track & Trace' solutions exist—including coding, tamper-evident seals, aggregation, and GS1 standards—but their high installation costs limit their use primarily to developed countries.
• The SADC region has seen pharmaceutical FDI growth from 2005 to 2019, with South Africa receiving the largest share at $892.6 million, primarily from the UK and US.

APA

SHIPALANA, P., MATEMA, T., & VAN DER WESTHUIZEN, H. (2020). Counterfeit Pharmaceuticals: A Major Threat to Public Health. South African Institute of International Affairs. https://saiia.org.za/wp-content/uploads/2020/07/Policy-Insights-87-shipalana-matema-VDWesthuizen.pdf

Chicago

SHIPALANA, PALESA, TAWANDA MATEMA, and HANNEKE VAN DER WESTHUIZEN. Counterfeit Pharmaceuticals: A Major Threat to Public Health. South African Institute of International Affairs, 2020. https://saiia.org.za/wp-content/uploads/2020/07/Policy-Insights-87-shipalana-matema-VDWesthuizen.pdf.

Wikipedia

{{cite report |last1=SHIPALANA |first1=PALESA |last2=MATEMA |first2=TAWANDA |last3=VAN DER WESTHUIZEN |first3=HANNEKE |title=Counterfeit Pharmaceuticals: A Major Threat to Public Health |publisher=South African Institute of International Affairs |date=July 2020 |url=https://saiia.org.za/wp-content/uploads/2020/07/Policy-Insights-87-shipalana-matema-VDWesthuizen.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{shipalana2020counterfeit, author = {SHIPALANA, PALESA and MATEMA, TAWANDA and VAN DER WESTHUIZEN, HANNEKE}, title = {{Counterfeit Pharmaceuticals: A Major Threat to Public Health}}, institution = {South African Institute of International Affairs}, year = {2020}, month = jul, url = {https://saiia.org.za/wp-content/uploads/2020/07/Policy-Insights-87-shipalana-matema-VDWesthuizen.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }